



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### A type III complement factor D deficiency

**Citation for published version:**

Sng, CCT, O'Byrne, S, Prigozhin, DM, Bauer, MR, Harvey, JC, Ruhle, M, Challis, BG, Lear, S, Roberts, LD, Workman, S, Janowitz, T, Magiera, L, Doffinger, R, Buckland, MS, Jodrell, DJ, Semple, RK, Wilson, TJ, Modis, Y & Thaventhiran, JED 2018, 'A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway', *Journal of Allergy and Clinical Immunology*.  
<https://doi.org/10.1016/j.jaci.2018.01.048>

**Digital Object Identifier (DOI):**

[10.1016/j.jaci.2018.01.048](https://doi.org/10.1016/j.jaci.2018.01.048)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Journal of Allergy and Clinical Immunology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



James N. Moy, MD<sup>a</sup>  
Ian M. Paul, MD, MSc<sup>b</sup>  
Stanley J. Szeffler, MD<sup>c</sup>  
Daniel J. Jackson, MD<sup>d</sup>  
Anne M. Fitzpatrick, PhD<sup>e</sup>

on behalf of the National Institutes of Health/National Heart, Lung, and  
Blood Institute AsthmaNet

From <sup>a</sup>the Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga; <sup>b</sup>the Department of Public Health Sciences, College of Medicine, Penn State University, Hershey, Pa; <sup>c</sup>Children's Hospital Oakland Research Institute, Oakland, Calif; <sup>d</sup>the Division of Allergy/Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass; <sup>e</sup>Stroger Hospital of Cook County, Department of Pediatrics, Rush University Medical Center, Chicago, Ill; <sup>f</sup>the Department of Pediatrics, College of Medicine, Penn State University, Hershey, Pa; <sup>g</sup>Children's Hospital Colorado, the Breathing Institute, and the University of Colorado School of Medicine, Aurora, Colo; and <sup>h</sup>Pediatrics, Section of Allergy, Immunology and Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, Wis. E-mail: [anne.fitzpatrick@emory.edu](mailto:anne.fitzpatrick@emory.edu).

This study was supported by the National Institutes of Health (grant nos. HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, TR000454, K23AI104780, and K24AI106822).

Disclosure of potential conflict of interest: C. R. Morris has received royalties from a patent from Lifetrents/UCSF-Benioff Children's Hospital Oakland; and has consultant arrangements with Pfizer, Kantar Consulting, LEK Consulting, and Nestle. D. T. Mauger has received a grant from the National Institutes of Health and has received nonfinancial support from Merck and GlaxoSmithKline. J. N. Moy has received a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute. I. M. Paul has received a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute; and has received personal fees from Pfizer, Johnson & Johnson, Boehringer Ingelheim, and the Rocky Mountain Poison & Drug Center. S. J. Szeffler has received grants from the National Heart, Lung, and Blood Institute, AsthmaNet, and GlaxoSmithKline; has received compensation from Merck for participation in an advisory panel; has consulted for Boehringer Ingelheim; has participated in manuscript preparation and advisory boards for Genentech; has participated in advisory meetings for GlaxoSmithKline; has provided guidance in application of an inflammation monitoring device for Aerocrine; has participated in development of follow-up The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II study for Novartis; has received payment for assistance in educating investigators regarding severe asthma in children and also for guidance in new product development from AstraZeneca; has received payment for advice on development of new medication from Daiichi Sankyo; has received payment for assistance in designing and monitoring a pediatric asthma study for a new medication from Roche; and has received payment for participation in an asthma advisory panel for a new medication from Teva. D. J. Jackson has received a grant from the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases and has received personal fees from Boehringer Ingelheim, Commense, GlaxoSmithKline, Merck, and Novartis. A. M. Fitzpatrick has received a grant from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.

## REFERENCES

1. Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szeffler SJ, et al. Acetaminophen versus ibuprofen in young children with mild persistent asthma. *N Engl J Med* 2016;375:619-30.
2. McBride JT. The association of acetaminophen and asthma prevalence and severity. *Pediatrics* 2011;128:1181-5.
3. Fitzpatrick AM, Teague WG, Holguin F, Yeh M, Brown LA. Severe Asthma Research Program. Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. *J Allergy Clin Immunol* 2009;123:146-52.e8.
4. Morris CR, Poljakovic M, Lavisha L, Machado L, Kuypers F, Morris SM Jr. Decreased arginine bioavailability and increased arginase activity in asthma. *Am J Respir Crit Care Med* 2004;170:148-53.
5. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *J Am Med Assoc* 2004;294:81-90.
6. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. *Blood* 2008;110:104-12.
7. Fitzpatrick AM, Stephenson ST, Hadley GR, Burwell L, Penugonda M, Simon DM, et al. Thiol redox disturbances in children with severe asthma are associated

with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)-like 2. *J Allergy Clin Immunol* 2011;127:1604-11.

8. Stephenson ST, Hadley G, Brown LA, Fitzpatrick AM. Decreased expression of acetaminophen-metabolizing enzymes and glutathione in asthmatic children after acetaminophen exposure. *J Allergy Clin Immunol* 2012;129:867-9.
9. Lara A, Khatri SB, Wang Z, Comhair SA, Xu W, Dweik RA, et al. Alterations of the arginine metabolome in asthma. *Am J Respir Crit Care Med* 2008;178:673-81.

Available online March 5, 2018.  
<https://doi.org/10.1016/j.jaci.2018.01.045>


## A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway




### To the Editor:

We investigated an alternative complement pathway (AP) deficiency in a patient with absent alternative pathway hemolytic activity but normal classical pathway hemolytic activity recovering from invasive meningococcal infection (for patient and sibling details, see [Patient details](#) in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Serum reconstitution with proximal AP components suggested a factor D (FD) deficiency ([Fig 1, A](#)). Sanger sequencing of *CFD* identified a rare homozygous missense mutation (c.602G>C) in exon 4 in the patient (II-1) and sibling (II-2), resulting in an arginine to proline substitution (p. R176P) (see [Fig E1, A](#), and reference [E9](#) in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). This genotype cosegregated with an alternative pathway hemolytic activity-null phenotype, as the parents, both heterozygotes, had normal alternative pathway hemolytic activity ([Fig 1, B](#)). In contrast to previously confirmed FD deficiencies,<sup>1-3</sup> all members of the pedigree had normal levels of circulating FD, as corroborated by Western blot (see [Fig E1, B](#)). Meanwhile, identical circular dichroism spectra and melting curves of recombinant wild-type (WT) and R176P FD precluded gross changes in FD structure or stability, suggesting a functional deficiency ([Fig 1, C](#), and see [Fig E1, C](#)). We assessed the cleavage of C3b-bound factor B (FB) by recombinant WT and mutant FD (R176P, R176A, R176Q). WT FD could cleave C3b-bound FB to produce fragments Bb and Ba. Conversely, R176P FD demonstrated diminished *in vitro* catalytic activity at all concentrations and had negligible activity at physiological concentration (0.04 μmol/L) ([Fig 1, D](#), and see [Fig E1, D](#)). Reconstitution of FD-depleted serum with R176P FD also demonstrated impaired AP-mediated hemolysis (see [Fig E1, E](#)).

FD's serine protease activity depends on obligatory binding to the C3bB complex via 4 exosite loops (residues 132-135, 155-159, 173-176, 203-209). This leads to rearrangement of the self-inhibitory loop (199-202), allowing realignment of His41 and Asp89 with Ser183 to form the active catalytic triad (see [Fig E2, A and B](#), in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)).<sup>4,5</sup> Mutation R176P lies outside the active site, within one of the FB-binding exosite loops. We used molecular dynamics (MD) simulations to study how the R176P mutation affects the FD protein fold (see [Fig E2, C](#)). In mutant FD, we observed a rearrangement of the exosite loop 155-161 within 50 nanoseconds of simulation ([Fig 2, A](#)). This was unexpected because loop 155-161 was not in direct contact with residue 176. Average structures generated from the final 50 nanoseconds of simulation



**FIG 1.** Assessing the contribution of mutation R176P to AP dysfunction. **A**, Alternative pathway hemolytic activity (AP50) assay assessing patient serum supplemented with properdin (P), FB, or FD. **B**, The immediate family pedigree of the patient with the *CFD* genotype, serum AP50, and serum FD concentrations displayed. *D* represents the WT allele and *d*, the mutant allele (c.602G>C). **C**, Thermal shift assay of WT and R176P FD. **D**, Serial dilutions of recombinant WT or R176P FD were incubated with C3b and FB. The SDS-PAGE gel, stained with AcquaStain, shows the individual proteins and resultant products.



**FIG 2.** Defining the effects of the R176P mutation on FD function. **A** and **B**, FB-binding exosite loop 155-167 assumes a new conformation in mutant FD simulation. Arrows highlight average C $\alpha$  position shifts of 2 residues that bind C3bB in the R176P FD simulation. **C**, Loss of shape complementarity at the FD-C3bB interface. FD exosite loops from published cocrystal structures (white, Protein Data Bank ID: 2XWB) overlaid with the simulated loops of WT and mutant FD. **D**, Distance sampled between the active site Ne2 nitrogen of His41 and O $\gamma$  of Ser183 during each simulation. The shorter distance is necessary for catalytic activity. **E** and **F**, Surface plasmon resonance binding measurement of enzymatically inactive recombinant FD (R176P/S183A or WT/S183A) to C3bB complex. **G**, Steady state kinetics for Z-Lys-SBzl cleavage by WT, R176P, R176A, and catalytically inactive control S183A FD. RMSD, Root-mean-square deviation.

for WT and mutant FD (R176P and R176A) demonstrated that key FB-binding residues Asp161 and Arg157 were shifted by 4.3 Å and 1.9 Å, respectively (C $\alpha$  average position) (Fig 2, B). Superimposing these MD average structures onto the crystal structure of the C3bB-D complex revealed that Asp161 and Arg157 assumed a conformation that no longer supported binding due to loss of shape and charge complementarity to the FB surface (Fig 2, C). The other 3 exosite loops retained their binding-competent conformations. After assuming the new conformation, exosite loop 155-161 demonstrated higher conformational mobility (root mean square fluctuation) relative to WT (Fig E2, D and E). In contrast, the mobility of loops containing catalytic residues His41 and Asp89 decreased in the mutants. Using the distance between His41 and Ser183 during MD simulations as a proxy for the active site conformation, we observed that WT could sample the short distance necessary for a catalytically active conformation (Fig 2, D). Conversely, in both mutant simulations, the distance remained larger, consistent with His41 pointing away from the active site. Therefore, in

addition to disruption of key FB-binding residues, mutations R176P and R176A appear to stabilize the self-inhibited conformation of free FD.

To assess the binding of FD to C3bB, we used surface plasmon resonance. Coinjection of catalytically inactive FD (WT/S183A) with FB demonstrated a dose-dependent increase in binding to C3b and complex formation (Fig 2, E). In contrast, R176P/S183A FD lacked any detectable binding (Fig 2, F). Consistent with the stochastic transitions of free WT FD to the active conformation observed in the MD simulation, FD has a low level of esterolytic activity toward a small synthetic substrate, Z-Lys-SBzl (Fig 2, D). Surprisingly, R176P FD demonstrated a loss of esterolytic activity similar to the active site mutant, S183A (see Fig 2, G).

Deficiency of properdin, the most common AP deficiency, can result from absent (type I), low (type II), or normal but nonfunctioning (type III) protein levels (for reference, see reference E10 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Meanwhile, previously confirmed deficiencies of activating complement serine proteases have all



resulted in low or absent gene product. We have identified a unique deficiency: R176P FD is fully expressed and stable, but enzymatically inert, constituting a functional or type III deficiency. Recent preclinical evidence<sup>6</sup> that FD-deficient mice are susceptible to diabetes prompted metabolic assessment in the FD-deficient patients. No abnormality was detected (for details, see Functional FD deficiency does not result in impaired oral glucose tolerance section, Fig E3, and Table E1 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)).

Overactivation of AP is implicated in numerous inflammatory disorders, including age-related macular degeneration. Therefore, blockade of the AP by targeting the rate-limiting enzyme, FD, is an attractive approach to controlling disease progression. An anti-FD Fab fragment targeting the 2 distal exosite loops has shown some benefit in phase II clinical trials for treatment of dry age-related macular degeneration.<sup>7</sup> *In vitro* studies indicate that it inhibits binding to the C3bB complex but increases esterolytic activity toward small-molecule substrates.<sup>8</sup> This may result in unwanted clinical effects due to nonspecific activity or limit its efficacy *in vivo*. In the case of R176P FD, both FB-binding and esterolytic activity are abrogated through exosite hindrance and stabilization of the self-inhibited state. Loop 173-176 is thus a promising target for allosteric inhibitors of FD that stabilize the inhibitory loop in addition to binding-blockade. A structure-based design approach to targeting FD has recently succeeded in identifying candidate FD inhibitors where high-throughput screens had failed,<sup>9</sup> highlighting the benefits of integrating structural information into candidate drug screens. Comprehensive definition of the structural and molecular determinants of *in vivo* FD activity is critical for this. This study of the R176P mutation demonstrates how in-depth mechanistic analysis of rare complement deficiencies can deliver such insight validated clinically by *in vivo* human evidence of AP blockade.

Our acknowledgments can be found in this article's Online Repository (at [www.jacionline.org](http://www.jacionline.org)).

Christopher C. T. Sng, MB BChir<sup>a,\*</sup>

Sorcha O'Byrne, BSc<sup>b,\*</sup>

Daniil M. Prigozhin, PhD<sup>c,\*</sup>

Matthias R. Bauer, PhD<sup>d,\*</sup>

Jennifer C. Harvey, BSc<sup>e</sup>

Michelle Ruhle, BBiomedSc<sup>f</sup>

Ben G. Challis, PhD<sup>g</sup>

Sara Lear, MBBS<sup>h</sup>

Lee D. Roberts, PhD<sup>h</sup>

Sarita Workman, RN MSc<sup>e</sup>

Tobias Janowitz, PhD<sup>a</sup>

Lukasz Magiera, PhD<sup>a</sup>

Rainer Doffinger, PhD FRCPATH<sup>b</sup>

Matthew S. Buckland, PhD FRCPATH<sup>e</sup>

Duncan J. Jodrell, DM MSc FRCP<sup>a</sup>

Robert K. Semple, MB PhD<sup>g,i</sup>

Timothy J. Wilson, PhD<sup>j</sup>

Yorgo Modis, PhD<sup>c</sup>

James E. D. Thaventhiran, PhD FRCPATH<sup>a,b,k,l</sup>

Addenbrooke's Hospital, Cambridge, United Kingdom; <sup>h</sup>the Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds Institute of Genetics, Health and Therapeutics (LIGHT) Laboratories, University of Leeds, Leeds, United Kingdom; <sup>i</sup>the University of Edinburgh Centre for Cardiovascular Sciences, Queen's Medical Research Institute, Little France Crescent, Edinburgh, United Kingdom; <sup>j</sup>the Department of Microbiology, Miami University, Oxford, Ohio; and <sup>k</sup>the MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom. E-mail: [jedt2@cam.ac.uk](mailto:jedt2@cam.ac.uk).

\*These authors contributed equally to this work.

J.E.D.T. is supported by an MRC Clinician Scientist Fellowship (MR/L006197/1). This work was funded by Cambridge Biomedical Research Centre Inflammation, Infection and Immunotherapeutics Pump-Priming Grant (BRC III PPG) funding and a Wellcome Trust Senior Research Fellowship to Y.M. (101908/Z/13/Z). R.K.S. is funded by the Wellcome Trust (grant WT098498 and strategic award 100574/Z/12/Z), the United Kingdom Medical Research Council (MRC\_MC\_UU\_12012/5), and the United Kingdom National Institute for Health Research, Cambridge Biomedical Research Centre. T.J. is funded by Cancer Research UK (Clinician Scientist Fellowship C42738/A24868). B.G.C. is now a full-time employee of AstraZeneca.

Disclosure of potential conflict of interest: B. Challis is employee of AstraZeneca. S. Lear's institution received a grant from Cambridge Biomedical Research Centre Pump Priming Grant for this work. S. Workman received a grant from CSL Behring for other works; honorariums from LFB S.A. (France) and Biotest; and support for meetings from Grifols, CSL Behring, Bio Products Laboratory Ltd, and Octapharma. The rest of the authors declare they have no relevant conflict of interest.

## REFERENCES

- Hiemstra PS, Langelier E, Compier B, Keepers Y, Leijh PC, van den Barselaar MT, et al. Complete and partial deficiencies of complement factor D in a Dutch family. *J Clin Invest* 1989;84:1957-61.
- Biesma DH, Hannema AJ, van Velzen-Blad H, Mulder L, van Zwieten R, Kluijff I, et al. A family with complement factor D deficiency. *J Clin Invest* 2001;108:233-40.
- Sprong T, Roos D, Weemaes C, Neeleman C, Geesing CL, Mollnes TE, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. *Blood* 2006;107:4865-70.
- Narayana SV, Carson M, el-Kabbani O, Kilpatrick JM, Moore D, Chen X, et al. Structure of human factor D: a complement system protein at 2.0 Å resolution. *J Mol Biol* 1994;235:695-708.
- Fornieris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. *Science* 2010;330:1816-20.
- Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves beta cell function in diabetes. *Cell* 2014;158:41-53.
- Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. *Sci Transl Med* 2017;9:pii:eaaf1443.
- Katschke KJ Jr, Wu P, Ganesan R, Kelley RF, Mathieu MA, Hass PE, et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. *J Biol Chem* 2012;287:12886-92.
- Maibaum J, Liao SM, Vulpatti A, Ostermann N, Randl S, Rudisser S, et al. Small-molecule factor D inhibitors targeting the alternative complement pathway. *Nat Chem Biol* 2016;12:1105-10.

Available online March 6, 2018.

<https://doi.org/10.1016/j.jaci.2018.01.048>

## Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci



### To the Editor:

The criterion standard in respiratory research is the investigation of biosamples of the lower airway, which are usually obtained by bronchoscopy. However, this is an invasive procedure, with a substantial burden to patients that is also associated with high costs.

Recent studies have suggested that nasal brushings may provide a less invasive source of airway epithelial cells that

From <sup>a</sup>the Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; <sup>b</sup>the Department of Clinical Immunology, Cambridge University Hospitals National Health Service Trust, Addenbrooke's Hospital, Cambridge, United Kingdom; <sup>c</sup>the Molecular Immunity Unit, Department of Medicine, Medical Research Council (MRC) Laboratory of Molecular Biology, Cambridge, United Kingdom; <sup>d</sup>the Division of Structural Studies, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom; <sup>e</sup>the Department of Immunology, Royal Free London National Health Service Foundation Trust, London, United Kingdom; <sup>f</sup>the Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; <sup>g</sup>the Wellcome Trust-MRC Institute of Metabolic Science, and <sup>k</sup>the Department of Medicine, University of Cambridge,

## PATIENT DETAILS

A 19-year-old, South Asian female presented with a 24-hour history of high fever, rigors, delirium, and diarrhea. On clinical examination, she was febrile with a purpuric rash and a reduced level of consciousness (Glasgow Coma scale score: 9 of 15). Intravenous antibiotic therapy was initiated for provisionally diagnosed meningococcal septicemia. She was intubated and transferred to the intensive care unit where she developed disseminated intravascular coagulation, for which she received treatment. Results from blood cultures drawn at the time of admission confirmed an infection with *Neisseria meningitidis* serogroup Y. Her clinical condition improved with intensive care support and antimicrobial therapy. She was discharged after 2 weeks with minimal sequelae including bilateral leg scarring, a sacral pressure sore, and mild bilateral hearing loss.

At the age of 5 years, she had received bilateral tympanostomy tubes for recurrent ear infections and otitis media with effusion but had no other unusual infections as a child. She received the full course of childhood vaccinations as per the national immunization schedule.

On screening for immunodeficiency, laboratory measurement demonstrated a normal full blood count with normal counts of lymphoid cells. The titers of C3, C4, mannose-binding lectin and C1q were within normal range, but there was undetectable AP50 in conjunction with normal classical pathway hemolytic activity. In view of her complement deficiency, she was prescribed lifelong phenoxymethylpenicillin as antimicrobial prophylaxis. She was also vaccinated for meningitis serogroups A, C, W-135, and Y; meningitis C; pneumococcus; and *Haemophilus influenza B* to which she developed high antibody titer responses.

Her sole sibling, a younger male, who was homozygous for the same mutation, leading to an identical pattern on immunodeficiency screening, was healthy at assessment. He reported no excess of infections in the past. Of note, he reported having been treated empirically for suspected meningitis, at age 11 years, while travelling in Mauritius from which he recovered with no sequelae after a standard course of antibiotics.

## FUNCTIONAL FD DEFICIENCY DOES NOT RESULT IN IMPAIRED ORAL GLUCOSE TOLERANCE

Recent preclinical evidence<sup>E1</sup> that FD regulates insulin secretion prompted metabolic assessment of the patient and her sibling. They had a body mass index of 19.3 kg/m<sup>2</sup> and 23.1 kg/m<sup>2</sup>, respectively. Fasting venous plasma glucose (5.2–5.4 mmol/L) and insulin (29–39 pmol/L) levels were normal in both subjects (Fig E3). Similarly, plasma glucose excursions were normal in response to an oral glucose (75 g) challenge. At 120 minutes following glucose administration, glucose levels remained normal (4.0 mmol/L). Furthermore, circulating concentrations of leptin and adiponectin, adipokines that regulate insulin sensitivity, were normal, as were fasting lipid profiles in both subjects. Thus, glucose homeostasis is not impaired in the context of genetic, and therefore lifelong, FD deficiency.

These results are consistent with the finding that FD knockout mice developed impaired glucose tolerance only on a long-term diabetogenic diet. This suggests that FD may contribute little to glucose homeostasis in the absence of prolonged metabolic stress. Alternatively, the role of FD in glucose homeostasis could be independent of binding to C3bB or independent of its serine protease activity and, by extension, independent of its

downstream effects on the complement cascade. While congenital deficiency of FD alone may not lead to insulin insufficiency, Lo et al's<sup>E1</sup> findings warrant observation of oral glucose tolerance in such FD-deficient patients under extreme metabolic stress and at older age. Further research will be required to understand the role of FD in glucose homeostasis and FD-deficient family pedigrees offer a useful clinical insight to this question.

## METHODS

### Informed consent statement

All study participants gave their informed consent as appropriate under approved protocols from local institutional review boards. The research was conducted at University College London and the University of Cambridge under approved protocols (#04/Q0501/119 for affected individuals, #07/H0720/182 for family members).

### AP50 measurement

AP100 RC003.1 Kit (Binding Site, Birmingham, UK) agar-chicken erythrocyte plates were prepared according to the manufacturer's instructions, with kit control and calibration solutions added. Then 5-μL aliquots of test serum were added to individual wells on the plates over ice. The loaded plates were then stored at 4°C for 18 hours to allow radial diffusion of serum components, followed by incubation at 37°C for 90 minutes to develop zones of lysis. The plates were then digitally scanned at high resolution, and the diameters of zones of lysis were measured using ImageJ 1.x computer software (National Institutes of Health, Bethesda, Md). Representative plates were selected for figures. The diameter of lysis correlates with AP50 and is expressed out of 100% relative to kit control. Purified human FD, FB, and properdin for reconstitution assays were purchased from Complement Tech (Tyler, Tex).

### Sanger sequencing

Genomic DNA was isolated from blood samples with QIAamp Kits (Qiagen, Hilden, Germany). The *CFD* gene PCR was performed with primers annealing to intron sequences close to each exon as described previously.<sup>E2</sup> Specifically, regarding the R176P mutation, a 258-bp genomic fragment comprising exon 4 was amplified by PCR with the primers 5'-CTGGGGCA TAGTCAACCAC-3' and 5'-TGGGCCCTGTTCTACTTG-3'. The cDNA numbering for the *CFD* variant identified is based on transcript Ref Seq accession no. NM\_001928/Ensembl accession no. ENST00000327726.6 (National Center for Biotechnology Information, Bethesda, Md), beginning at the ATG start codon. The genomic coordinates refer to the GRCh37 genome build.

### Western blot analysis

Pooled control and the patient serum were diluted to 1:40 in Tris-buffered saline and resolved by SDS-PAGE on NuPAGE 4% to 12% Bis-Tris Gels, then blotted to nitrocellulose membranes. FD was detected using goat anti-human FD (AF1824; R&D Systems, Minneapolis, Minn) and donkey anti-goat-IgG IRDye 680CW (LI-COR Biosciences, Lincoln, Neb) secondary antibodies. The membranes were imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences).

### Recombinant CFD expression and purification

Lentiviral transfer plasmid, envelope plasmid (pMD2.G; gift from Didier Trono; AddGene plasmid #12260; Cambridge, Mass) and packaging plasmid (psPAX2; AddGene; gift from Didier Trono; AddGene plasmid #12259) were used to transfect HEK293T cells to produce lentiviral particles. The transfer vector (modified pLenti-CMV-GFP-Puro; gift of Eric Campeau; AddGene plasmid #17448) included human FD cDNA (WT, R176P, R176A, S183A) with C-terminus hexahistidine tag upstream of an IRES-Thy1.1 and a puromycin resistance gene (Puro<sup>R</sup>). Transfection was carried out using Lipofectamine 3000 and, after 24 hours, the media containing the lentiviral particles was used immediately to stably transduce newly plated HEK293T cells. After puromycin selection, stably transduced 293T cells were incubated with FreeStyle media (Gibco, Thermo Fisher Scientific, Waltham, Mass)

supplemented with 6X Glutamax and 2 mmol/L valproic acid. After 7 to 14 days, secreted recombinant CFD was purified from this media using cobalt immobilized metal affinity chromatography. CFD was eluted in 150 mmol/L imidazole in PBS and buffer exchanged by centrifugal concentration (Vivaspin 20; 10,000 Da pore size; Sartorius, Göttingen, Germany). Purity of the sample was confirmed on SDS-PAGE and mass spectrometry.

### Measuring *in vitro* catalytic activity of recombinant FD

Purified human C3b and FB were purchased from Complement Technology. Recombinant WT, R176P, or R176A FD were mixed in varying concentrations (1.0  $\mu\text{mol/L}$ , 0.2  $\mu\text{mol/L}$ , 0.04  $\mu\text{mol/L}$ ) with C3b (1.0  $\mu\text{mol/L}$ ) and FB (1.0  $\mu\text{mol/L}$ ) in veronal buffer (Lonza, Basel, Switzerland) with 10 mmol/L  $\text{MgCl}_2$  to a final volume of 20  $\mu\text{L}$ . Reaction tubes were incubated for 10 minutes at 37°C before the addition of sample loading buffer (NuPAGE LDS Sample Buffer, Thermo Fisher Scientific) to terminate the reaction. The samples were then heated to 70°C for 10 minutes and resolved by SDS-PAGE on a Novex NuPAGE 4% to 12% Bis-Tris Gel. The gels were developed overnight with AcquaStain (Bulldog Bio, Portsmouth, NH), washed for 1 hour with distilled water, dried, and digitally scanned at high resolution. Analysis of percentage cleavage of FB was calculated by densitometry analysis using ImageJ 1.x computer software. Statistical comparisons between WT and R176P FD activity were performed at each concentration, from 4 independent experiments using the Kruskal-Wallis nonparametric *t* test.

### Circular dichroism spectroscopy and thermal shift assay

WT and R176P catalytically inactive (S183A) proteins were purified by size exclusion chromatography in chloride-free 0.1 mol/L sodium phosphate pH 7.0, diluted to a concentration of 2 mg/mL (72.4  $\mu\text{mol/L}$ ), and loaded into a 0.1-mm quartz sample cell. Circular dichroism spectra were recorded at 20°C on a Jasco J-810 spectropolarimeter (Oklahoma City, Okla) equipped with a Jasco PTC-348WI temperature controller. Spectra were acquired from 190 to 260 nm with 0.1-nm resolution and 1-nm bandwidth. Final spectra are the sum of 20 scans acquired at 50 nm/min. For the thermal shift assay, 2  $\mu\text{g}$  of protein were mixed with SYPRO Orange (Fisher Scientific UK Ltd, Loughborough, UK) in PBS with 25 mmol/L HEPES and fluorescence data acquired on a Viia 7 real-time PCR system with thermal denaturation over increasing temperatures observed using 1°C intervals.

### MD simulation of mutant FD

Starting models were derived from crystal structures of S183A FD (Protein Data Bank [PDB] ID: 2XW9, 1.2 Å resolution) reported previously.<sup>E3</sup> The catalytic residue was reverted to serine during the MD setup. Coot<sup>E4</sup> was used to place the Pro176 side chain in the Arg176 experimental density while minimizing clashes with surrounding atoms and aiming to achieve a favorable initial geometry. The resulting structures were further adjusted in UCSF Chimera (Resource for Biocomputing, Visualization, and Informatics, San Francisco, Calif)<sup>E5</sup>. The GROMACS package (Gromacs, University of Groningen, Groningen, The Netherlands)<sup>E6</sup> was used to set up and run MD simulations. The AMBER99SB-ILDN force field (Gromacs)<sup>E7</sup> and TIP3P water model were used and the structures placed in dodecahedral boxes with 10 Å padding and surrounded with solvent including water and 150 mmol/L NaCl. Following steepest gradient energy minimization, a modified Berendsen thermostat (2 groups, time constant 0.1 picoseconds, temperature 310 K) followed by a Berendsen barostat (isotropic, coupling constant 0.5 picoseconds, reference pressure 1 bar) were coupled to the system over 100 picoseconds. One hundred–nanosecond runs of unrestrained MD trajectories were produced. Following removal of periodic boundary condition artefacts, MD runs were visualized and analyzed in Chimera and bulk statistics extracted using GROMACS analysis routines.

### Surface plasmon resonance

Binding experiments were carried out based on established protocol using a Biacore T200 instrument.<sup>E8</sup> FB and FD were buffer exchanged by gel filtration

into veronal buffer with 10 mmol/L  $\text{MgCl}_2$ . C3b was immobilized on the CM5 chip by amine coupling to achieve 8000 resonance units. A dual injection program was designed where 0.1  $\mu\text{mol/L}$  or 1  $\mu\text{mol/L}$  FB was injected at a flow rate of 30  $\mu\text{L/min}$  for 3 minutes, followed by a second injection of a mix of 0.1  $\mu\text{mol/L}$  or 1  $\mu\text{mol/L}$  FB and FD at 30  $\mu\text{L/min}$  for 4 minutes. After 5 minutes for dissociation, the chip was regenerated by 3 5-minute washes in 40 mmol/L acetate + 3 mol/L NaCl (pH 5.5). The chip was reequilibrated in assay buffer for 5 minutes. Catalytically inactive FD (S183A) or double mutant R176P/S183A were used to emulate the binding response of WT or R176P, respectively, while preventing cleavage of FB and subsequent dissociation of the complex.

### Esterolytic activity of FD


Z-Lys-SBzl was purchased from Sigma-Aldrich (St. Louis, Mo) in powder form and reconstituted to 100 mmol/L in 70% dimethyl sulfoxide. The assay buffer consisted of 50 mmol/L HEPES (pH 7.5), 220 mmol/L NaCl and 2 mmol/L of Ellman reagent (5,5-dithio-bis-[2-nitrobenzoic acid]; Sigma-Aldrich). Each reaction mixture contained FD (80 nmol/L), variable Z-Lys-SBzl concentrations (0.2–3.2 mmol/L) and 8% vol/vol of dimethyl sulfoxide in a final volume of 200  $\mu\text{L}$ . Solutions were prewarmed to 37°C before addition of substrate to initiate the reaction. Hydrolysis of Z-lys-SBzl was measured using CLARIOstar FS microplate reader through equimolar formation of chromophore 2-nitro-5-thiobenzoate at 405 nm every 30 seconds for 90 minutes ( $\epsilon = 13,600 \text{ mol/L}^{-1}\text{cm}^{-1}$ ). The rate of hydrolysis was determined from linear slopes of the reaction curves. Reaction velocities, expressed in apparent turnover values were plotted against substrate concentration.

### Acknowledgment

We thank the patient and her family for their support of this work. J.E.D.T. would also like to thank Doug Fearon for many years of training and thoughtful review of the manuscript. J.C.H. and J.E.D.T. would like to thank Dr Christopher C. Bunn for mentorship and advice when initiating this research. We would like to thank Dr Simon Clark for thoughtful review of the manuscript.


### REFERENCES

- Lo JC, Ljubcic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves beta cell function in diabetes. *Cell* 2014;158:41–53.
- Sprong T, Roos D, Weemaes C, Neeleman C, Geesing CL, Mollnes TE, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. *Blood* 2006;107:4865–70.
- Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. *Science* 2010;330:1816–20.
- Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* 2010;66:486–501.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 2004;25:1605–12.
- Abraham MJ, Murtola T, Schulz R, Pall S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* 2015;1–2:19–25.
- Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins* 2010;78:1950–8.
- Katschke KJ Jr, Wu P, Ganesan R, Kelley RF, Mathieu MA, Hass PE, et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. *J Biol Chem* 2012;287:12886–92.
- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–91.
- Fredrikson GN, Westberg J, Kuijper EJ, Tijssen CC, Sjoholm AG, Uhlen M, et al. Molecular characterization of properdin deficiency type III: dysfunction produced by a single point mutation in exon 9 of the structural gene causing a tyrosine to aspartic acid interchange. *J Immunol* 1996;157:3666–71.




**FIG E1.** Mutation R176P results in a type III FD deficiency. **A**, Chromatograms for the DNA sequence adjacent to position c.602 are shown for each member of the pedigree. The identified variant is rare: the Exome Aggregation Consortium's ExAC database reports mutation R176P (variant 19:861943 G/C) at an allele frequency of  $1.049 \times 10^{-4}$ , with no homozygotes.<sup>E9</sup> **B**, Western blot analysis of FD in serum from the patient and healthy control. **C**, Secondary structural compositions of WT and R176P FD were evaluated using circular dichroism spectroscopy. **D**, Comparison of *in vitro* catalytic activity of recombinant WT, R176P, R176Q, and R176A FD in terms of FB cleavage. \*\*\* $P < .001$ ; \*\*\*\* $P < .0001$ . **E**, Recombinant WT and R176P FD were tested for the ability to reconstitute AP50 when added to FD-depleted serum.





**FIG E2.** Mutation R176P stabilizes the self-inhibited state of FD. **A**, Structure of free FD<sup>E3</sup> (PDB ID: 2XW9) showing the catalytic triad (Ser183-His41-Asp89) in an inactive conformation stabilized by the self-inhibitory loop 199-202 (red) and an ion bridge between Asp177 and Arg202. The exosite loops are shown in yellow. **B**, Structure of C3bB-bound FD<sup>E3</sup> (PDB ID: 2XWB) omitting the C3b and FB components. FD exosite loops retain a conformation similar to that of unbound FD. **C**, WT, R176P, and R176A structures were stable over 100 nanoseconds of unrestrained molecular dynamics simulation with explicit solvent. **D**, Root mean square fluctuation (RMSF) in WT and mutant FD over the second half of the trajectory. **E**, Differences in WT versus R176 RMSF mapped to the FD structure. MD predicted increased mobility in exosite loops, notably 155-167, and decreased mobility in loops carrying the catalytic His41 and Asp89 residues.



**FIG E3.** Assessment of glucose tolerance in patients with functional FD deficiency. Patient and sibling were given 75 g of oral glucose at 0 minutes and blood glucose was measured at regular intervals between 0 and 120 minutes. The *error bars* indicate the range of plasma glucose concentrations between the patient and sibling.

**TABLE E1.** Fasting measurements of metabolic parameters in the patient and sibling

Analyte	Patient	Sibling
Leptin (ng/mL)	10.6	11.3
Adiponectin ( $\mu$ g/mL)	9.7	6.5
NEFA ( $\mu$ mol/L)	391	212
Cholesterol (mmol/L)	4.2	4
HDL (mmol/L)	1.53	1.26
LDL (mmol/L)	2.3	2.3
Triglycerides (mmol/L)	0.8	0.9
HbA <sub>1c</sub> (mmol/mol)	36	35

*HbA<sub>1c</sub>*, Glycosylated hemoglobin; *HDL*, high-density lipoprotein; *LDL*, low-density lipoprotein; *NEFA*, nonesterified fatty acids.